BTI
ZNTL icon

Blue Trust Inc’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Blue Trust Inc’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-388
Closed -$1.59K – 3025
2024
Q3 		$1.59K Buy
388
+253
+187% +$920 ﹤0.01% 2622
2024
Q2 		$2.13K Buy
+135
New +$1.51K ﹤0.01% 2432
2023
Q3 		– Sell
-7
Closed – – 2327
2023
Q2 		$0 Sell
7
-9
-56% -$216 ﹤0.01% 2590
2023
Q1 		$0 Sell
16
-37
-70% -$749 ﹤0.01% 2674
2022
Q4 		$1K Sell
53
-31
-37% -$667 ﹤0.01% 2166
2022
Q3 		$2K Buy
+84
New +$2.3K ﹤0.01% 1850

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Blue Trust Inc's ZNTL Position: Q4 2024 in Review

Blue Trust Inc sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2024, closing a stake of 388 shares — an estimated $1.59K sold.

Blue Trust Inc first reported a position in ZNTL in Q3 2022 and held it in 6 quarters. The position peaked at $2.13K in Q2 2024. 142 funds tracked by Wall St. Rank hold ZNTL as of Q4 2024.

  • Blue Trust Inc reported no remaining Zentalis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Blue Trust Inc sold 388 Zentalis Pharmaceuticals shares in Q4 2024, an estimated $1.59K.
  • Blue Trust Inc first reported a position in Zentalis Pharmaceuticals in Q3 2022 and held it in 6 quarters.
  • Blue Trust Inc's Zentalis Pharmaceuticals position peaked at $2.13K in Q2 2024.
  • 142 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2024.

Based on Blue Trust Inc's 13F filing for Q4 2024, filed 22 Jan 2025.